United States
US 12,702,660 B2
Method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor
US 12,702,660 B2 is a granted patent from the United States Patent and Trademark Office (USPTO), dated 2026-08-11. Applicant: Eisai R&D Management Co., Ltd. Its PDF downloads from this page without an account, up to 5 a day.
- Applicant
- Eisai R&D Management Co., Ltd.
- Inventors
- Jianjun XIAO; Nathalie M. RIOUX; Victoria RIMKUNAS
- Publication date
- 2026-08-11
- Filing date
- 2021-11-23
- Document type
- B2 Granted patent
- Also written as
- US 12,702,660 B2 · US12702660 · 12702660
Abstract
The present invention relates to pharmaceutical compositions comprising an inhibitor of human ERα, and methods of cancer therapy using the ERα inhibitor. In particular, described herein are dosages of H3B-6545 with defined pharmacokinetic (PK) profiles that allow the inhibitor to be efficaciously and safely administered to a human subject in need thereof.
The opening of the abstract. The full text is in the PDF.
No account needed: 5 free downloads a day (5 left today). Batch downloads and Office Action citations need a free account.
Patent office website: United States Patent and Trademark Office (USPTO)
Look up another patent
Need many patents at once?
Paste a whole list of numbers. DownloadPatent finds the right version of each and packs the PDFs into one ZIP.
Sign up free